Although the disproportionate frequency of several immunologic disorders among women is well recognized, the effect of sex steroids on immunologic processes is unclear. We used an animal model, which has helped to elucidate the effect of corticosteroids in vivo, to 
Introduction
Corticosteroids can substantially alter the course of immunologic disease, and their therapeutic use is widespread. Other steroid hormones, such as sex steroids, also seem to be associated with changes in the clinical expression of several immunologic disorders. Immune hemolytic anemia, immune thrombocytopenic purpura (ITP),' and systemic lupus erythe- 1 . Abbreviations used in this paper: cpmc, cpm for the untreated control animal injected with unsensitized cells; cpmx, cpm for the experimental animal treated with steroid and injected with IgG-coated erythrocytes; Fc (IgG), Fc portion of immunoglobulin G; ITP, immune thrombocytopenic purpura; SSV, steroid suspension vehicle. matosus all occur more frequently in women than in men. Furthermore, the clinical course of exacerbation and remission in patients with these diseases may vary with changes in hormonal state, such as during pregnancy and the immediate post-partum period (1) (2) (3) .
One mechanism of corticosteroid action is the impairment of macrophage recognition of IgG-coated cells or IgG-containing immune complexes (4) . Observations in murine models suggest that sex hormones may also affect macrophage function (5, 6) . Recent studies in patients with ITP and immune hemolytic anemia demonstrate some beneficial effect from danazol, a synthetic androgen (7, 8) . In addition, estrogen metabolism reportedly is altered in systemic lupus erythematosus patients in a manner that produces increased estrogenic activity (9) . Despite these observations, the precise effect of sex steroids on immunologic processes is poorly understood.
We studied the effect of several steroid analogues, including sex steroids, on one aspect of the pathologic process in immune hemolytic anemia and ITP-splenic macrophage clearance of IgG-coated cells. We used an experimental model developed in the guinea pig, which we previously found helpful in elucidating the effect of corticosteroids on macrophage clearance of antibody and complement-coated erythrocytes (10, 1 1). Our data indicate that splenic macrophage receptor expression for the Fc portion of immunoglobulin G [Fc(IgG)] is modulated not only by corticosteroids, but by estradiol as well.
Methods
Female Hartley guinea pigs weighing 500-600 g were obtained from Dutchland Farms, Denver, PA. All studies were done with females except as noted. Steroid drugs were obtained from Steraloids, Inc. (Wilton, NH), except for danazol (Sterling Drug, Inc., New York, NY), and tamoxifen (Stuart Pharmaceuticals Div., Wilmington, DE), which were kindly supplied by the manufacturers. All animals were injected with an equal volume of a homogeneous suspension of steroid in a vehicle (SSV) consisting of 0.5% carboxymethylcellulose, 0.4% Tween 80, and 1.5% ethanol in isotonic saline. This suspension vehicle has been used in other laboratories for subcutaneous injection in animal models to examine the biologic effects of steroids (12) . Sham-treated animals received 1 ml of SSV alone, and the drug-treated animals received steroids suspended in SSV, injected subcutaneously in the dorsal neck fat pad every afternoon for 7 d. Each animal was studied on the day after the seventh injection. IgG anti-guinea pig erythrocyte antibody was prepared in rabbits and quantitated as previously described (10) . The IgG fraction was isolated by Sephadex G-200 chromatography and was free of IgM as determined by Ouchterlony analysis.
Clearance of IgG-coated erythrocytes. This model is identical to that previously reported by us (10) . Blood was drawn from guinea pigs by cardiac puncture and the washed erythrocytes were radiolabeled with 5"Cr-sodium chromate (New England Nuclear, Boston, MA) and then sensitized with an equal volume of IgG antibody, so as to be coated with 6,000 IgG molecules per erythrocyte. At least 1,500 IgG molecules per erythrocyte were necessary to accelerate clearance, similar to our previous observation (10, 13) . The number of IgG molecules per erythrocyte was determined as previously described (10) after radiolabeling of the IgG fraction with 25I (14). Animals pretreated with steroid or SSV control for 7 d were injected intravenously with 2.7 X 10' radiolabeled cells. Samples of blood were obtained from the retroorbital space 5-120 min after injection and were counted using a gamma counter (Gamma 8000, Beckman Instruments, Inc., Fullerton, CA).
Studies were also performed with heat-altered erythrocytes to investigate splenic clearance mediated by nonimmune mechanisms.
5"Cr-labeled erythrocytes were incubated for either 15 or 20 min at 500C in parallel with control erythrocytes incubated for the same time period at 370C. The cells were then placed at 370C for 5 min and then washed. The clearance of these heat-altered, radiolabeled erythrocytes was determined in the same way as the clearance of IgG-coated erythrocytes.
To determine the organ responsible for the clearance of sensitized and heat-altered erythrocytes, guinea pigs were sacrificed after the clearance studies. Their livers, kidneys, lungs, and spleens were removed, and whole organ 5"Cr radioactivity was determined in a gamma counter.
Clearance curves were plotted by expressing the number of blood cpm at each time point as a percentage of the number of cpm at 5 min. Clearance at time points 60, 90, and 120 min was analyzed to calculate a P value for the difference between control and experimental clearance curves using a Student's t test. In addition, for each day's clearance study, the percentage inhibition of clearance above control was calculated at 90 and 120 min according to the formula: percent inhibition = 100 X [1 - For experiments studying Fc (IgG) receptor activity, guinea pig erythrocytes were coated with 200, 400, and 800 molecules of IgG/ erythrocyte, as described above, and I ml of erythrocytes at a concentration of I X 10' cells/ml was incubated with the macrophage monolayers at room temperature for 45 min. For experiments studying C3 receptor activity, guinea pig erythrocytes were first sensitized with three different concentrations of IgM anti-guinea pig erythrocyte antibody Pg/10' erythrocytes), washed, and incubated with guinea pig serum as a complement source for 15 min at 37°C. 1 ml of these C3-coated, washed erythrocytes (I X 108 cells/ml) was then incubated with the macrophage monolayers as above. The monolayers were washed, air dried, stained with Wright-Giemsa, and 100 consecutive macrophages were inspected under oil immersion for the number of erythrocytes bound to each macrophage (18). Both the average number of erythrocytes bound per macrophage and the percentage of macrophages having three or more erythrocytes bound were determined.
The ability of soluble guinea pig IgG to inhibit splenic macrophage binding of IgG-coated erythrocytes was also studied. I ml of guinea pig IgG (Calbiochem Behring Corp., San Diego, CA), not possessing anti-guinea pig erythrocyte antibody activity, at concentrations from 0.1 to 100 ug/ml, was added to the macrophage monolayer just before incubation with IgG-coated erythrocytes, as described above. After incubation, the monolayers were washed and the average number of erythrocytes bound per macrophage and the percentage of macrophages having three or more erythrocytes bound were determined as above.
Results
Cortisol-pretreated guinea pigs exhibited impaired splenic clearance of IgG-coated erythrocytes. Pretreatment for 5-7 d with 90 mg/kg of cortisol impaired the clearance of IgG-coated erythrocytes in 19/26 animals by 40±6% compared with simultaneous sham-treated controls (Fig. I A) . At 2 h, 60±2% of the IgG-coated erythrocytes remained in the circulation in cortisol-treated animals, compared with 50±4% in shams. These results confirm the ability of corticosteroids to inhibit the clearance of IgG-coated erythrocytes (1 1).
Guinea pigs pretreated with estradiol, however, exhibited enhanced splenic clearance of IgG-coated erythrocytes, an effect opposite to that of cortisol (Fig. I A) . Pretreatment for 7 d with 90 mg/kg of estradiol enhanced the clearance of IgGcoated erythrocytes in 10/12 animals by 60±22% over simultaneous sham-treated controls. Only 31±6% of the IgG-coated cells remained in the circulation at 2 h, compared with 50±4% for sham controls. In 3 of 12 estradiol-treated animals, clearance was enhanced so that <10% of the IgG-coated erythrocytes remained in the circulation at 2 h. The difference between the clearance curves for the estradiol-treated and sham-treated groups of animals was significant at a level of P < 0.001. This ability of estradiol to enhance the clearance of IgGcoated erythrocytes depended on the amount of estradiol with which the animals were treated. Estradiol at doses of 90, 10, and I mg/kg given for 7 d to groups of 12, 6, and 8 animals, respectively, enhanced the clearance of IgG-coated erythrocytes to a similar extent (Fig. I B) . The percentages of cells remaining in the circulation at 2 h were 31±6%, 23±8%, and 27+6%, respectively, compared with 50±4% for the sham-treated controls. Doses of 0.1 and 0.001 mg/kg of estradiol given to groups of eight animals each for 7 d did not alter the clearance. Serum levels of estradiol were measured in male and female animals before and after 7-d treatment with I mg/kg of estradiol, the lowest dose at which an enhancement of clearance was demonstrated. Estradiol levels were also measured in sham-treated controls. Pretreatment estradiol levels in both males and females were from 10 to 56 pg/ml. Estradiol levels after sham treatment ranged from 10 to 69 pg/ml in males and females, but after treatment with estradiol, they ranged from 2 to 16 ng/ml, a thousandfold increase similar to the rise and absolute blood level of estradiol observed during pregnancy, where estradiol levels are in the range of 20-30 ng/ml (15, 16 (Table I) .
To determine whether the effect of estradiol on clearance of IgG-coated erythrocytes was due to an effect on immunemediated splenic clearance, or was due to a more general effect on the splenic macrophage or splenic blood flow, we measured the clearance of heat-altered erythrocytes in estradiol-treated and sham-treated animals (Fig. 2) . 51Cr-labeled guinea pig erythrocytes heated to 50°C for either 15 or 20 min were cleared in the spleen in a similar manner to IgG-coated erythrocytes. The percentage of cells in the circulation fell progressively over 2 h, and the rate of clearance was dependent on the length of time the cells were heated. 5"Cr quantitation in whole spleen, liver, kidneys, and lungs indicated that clearance also took place predominately in the spleen. Estradiol did not enhance the splenic clearance of heat-altered erythrocytes, as it did the clearance of IgG-coated erythrocytes.
Finally, we examined the effect of estradiol administered in vivo on the expression of Fc (IgG) receptor activity and C3 receptor activity by isolated splenic macrophages in vitro. Guinea pigs were treated for 7 d with 1-10 mg/kg of estradiol, or they received sham treatment without steroid. Their spleens were removed and splenic macrophage monolayers were prepared. Estradiol treatment had no consistent effect on the yield 164 Friedman, Nettl, and Schreiber the average number of erythrocytes bound was determined (Table III) .
per macrophage
Discussion
We employed an experimental animal model to define further the effect of steroid hormones on immune clearance. In these studies, we confirmed that pretreatment of guinea pigs with cortisol for 7 d impairs the splenic clearance of IgG-coated erythrocytes (11) . Similar to the experience in man, we observed that not all animals respond to corticosteroids in this fashion. 7 d of corticosteroid treatment impaired the clearance of IgGcoated erythrocytes in 73% (19/26) of the animals studied. In contrast to the effect of cortisol, the splenic clearance of IgG-coated erythrocytes in estradiol-pretreated animals was significantly enhanced (Fig. 1) . This observation could be explained by estradiol increasing blood flow to the spleen, increasing the number of macrophages in the spleen, or altering recognition of IgG-coated erythrocytes by splenic macrophages. We observed that estradiol does not enhance the clearance of heat-altered erythrocytes, which have a pattern of splenic clearance similar to that of IgG-coated erythrocytes (Fig. 2) . Furthermore, estradiol had no demonstrable effect on the small splenic clearance of erythrocytes not coated with IgG (not shown). The effect of estradiol, therefore, seems to be specific for immune-mediated clearance. If its effect was predominately to increase splenic blood flow or to increase the number or general activity of splenic macrophages, we would have expected estradiol-treated animals to clear heataltered erythrocytes more rapidly than sham-treated controls. The in vitro experiments employing splenic macrophages isolated from estradiol-pretreated animals further elucidate the mechanism of estradiol's action. The recognition of guinea pig erythrocytes by splenic macrophages depended upon the concentration of IgG on the erythrocyte surface. At a given concentration of IgG per erythrocyte, recognition of IgGcoated cells by splenic macrophages was increased in those macrophages isolated from estradiol-treated animals (Table II) Hormonal manipulation has been observed to alter the course of the lupus-like syndrome in the NZB/NZW mouse (6) . Estrogen treatment of these mice did not accelerate the clearance of IgG-coated erythrocytes. These studies differ from ours in that they were performed in a corticosteroid-sensitive species that produces autoantibodies and circulating immune complexes, whereas our studies were performed in normal guinea pigs, which, like man, are corticosteroid resistant. This species difference may also apply to other steroid hormones. Furthermore, the presence of circulating immune complexes may modulate the number of available splenic macrophage Fc (IgG) receptors (21) .
Tamoxifen is a nonsteroidal antiestrogen used in the palliation of estrogen receptor-positive breast cancer. Its effect in animal models depends on species and end organ. Thus, it can be an estrogen agonist, antagonist, or a partial agonist/ antagonist (22) . Our data suggest that tamoxifen acts as an estrogen agonist, less potent than estradiol, in influencing splenic macrophage Fc (IgG) receptor activity in normal guinea pigs. Whether tamoxifen inhibits or facilitates the effect of estradiol in this system is as yet unknown.
Recently, danazol, a synthetic androgen, has proven effective in some patients with immune thrombocytopenic purpura (7) or autoimmune hemolytic anemia (8) . Its mechanism of action is uncertain. Our data suggest that danazol's effect after 1 wk of treatment would be due to a mechanism other than an alteration of splenic macrophage recognition of IgG-coated cells. However, danazol treatment longer than 7 d may have additional effects.
Our experiments defining the effect of estradiol may be applicable to human immunologic disease, since several such disorders are disproportionately common among women. The clinical manifestation of these diseases may increase in phase with the menstrual cycle and in pregnancy, where estrogen levels increase dramatically (1-3). In IgG-induced immune hemolytic anemia, disease activity seems more profound during the later stages of pregnancy when estrogen levels are at their highest (23) . Estrogen-containing oral contraceptives have also been observed to exacerbate immune complex disease (24) . The minimal effective estradiol dose (1 mg/kg per day) and blood levels achieved (2-16 ng/ml) in our system are equivalent to the daily estrogen production and blood levels achieved during human pregnancy (25, 15, 16) . Our experimental design is patterned after pathologic processes in immune hemolytic anemia and immune thrombocytopenia. A direct effect of estrogens on splenic macrophage Fc (IgG) receptor-mediated clearance of IgG-coated erythrocytes or platelets may, in part, explain the variation in clinical expression of these disorders (1-3, 23, 24, 26) during changes in hormonal state, e.g., pregnancy.
These experiments raise the question of the effect of estrogens on other macrophage populations and on additional Fc (IgG) receptor-bearing cells that participate in the loalization of immune complexes. Such an effect might also enhance the clinical expression of immune complex disease by augmenting macrophage interaction with circulating immune complexes or by increasing immune complex deposition in certain tissues.
